• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression treatment no medication, traditional therapy and medications are not effective. The individual approach to treatment could be the solution.

Cue is an intervention platform that converts passively acquired sensor data from smartphones into personalized micro-interventions for improving mental health. We parsed the best natural treatment for anxiety and depression-fit personalized ML models for each subject using Shapley values to identify their feature predictors and reveal distinct features that are able to change mood with time.

Predictors of Mood

Depression is one of the world's leading causes of mental illness.1 However, only about half of those suffering from the disorder receive treatment1. In order to improve outcomes, doctors must be able to identify and treat patients who have the highest probability of responding to particular treatments.

The ability to tailor depression treatments is one method of doing this. Utilizing sensors for mobile phones, an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from the treatments they receive. With two grants awarded totaling over $10 million, they will employ these technologies to identify the biological and behavioral factors that determine response to antidepressant medications and psychotherapy.

The majority of research on predictors for depression treatment effectiveness (lovewiki.faith) has centered on clinical and sociodemographic characteristics. These include factors that affect the demographics such as age, sex and educational level, clinical characteristics like the severity of symptoms and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these aspects can be predicted by the information in medical records, very few studies have used longitudinal data to explore the causes of mood among individuals. Few also take into account the fact that mood varies significantly between individuals. It is therefore important to develop methods that permit the determination and quantification of the individual differences between mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can systematically identify various patterns of behavior and emotion that vary between individuals.

The team also created a machine-learning algorithm that can create dynamic predictors for the mood of each person's depression treatment nice. The algorithm combines the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype has been associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was not strong, however (Pearson r = 0,08, BH adjusted P-value 3.55 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is among the leading causes of disability1, but it is often underdiagnosed and undertreated2. Depressive disorders are often not treated due to the stigma that surrounds them, as well as the lack of effective interventions.

To facilitate personalized treatment, identifying patterns that can predict symptoms is essential. However, the current methods for predicting symptoms are based on the clinical interview, which has poor reliability and only detects a small variety of characteristics related to depression.2

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous, digital behavioral patterns gathered from sensors on smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements and capture a variety of unique behaviors and activity patterns that are difficult to record using interviews.

The study comprised University of California Los Angeles students with moderate to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or to clinical treatment based on the degree of their depression. Patients with a CAT DI score of 35 65 were assigned online support via an online peer coach, whereas those with a score of 75 patients were referred to psychotherapy in person.

At the beginning, participants answered an array of questions regarding their personal characteristics and psychosocial traits. These included age, sex, education, work, and financial status; if they were partnered, divorced or single; their current suicidal thoughts, intentions or attempts; and the frequency at that they consumed alcohol. The CAT-DI was used to assess the severity of depression symptoms on a scale from zero to 100. CAT-DI assessments were conducted every week for those who received online support and every week for those who received in-person care.

Predictors of Treatment Response

Research is focusing on personalization of depression treatment. Many studies are aimed at identifying predictors, which will help doctors determine the most effective drugs for each person. Pharmacogenetics in particular uncovers genetic variations that affect how the human body metabolizes drugs. This allows doctors select medications that are likely to be the most effective for each patient, while minimizing the amount of time and effort required for trials and errors, while avoid any negative side effects.

Another promising method is to construct models for prediction using multiple data sources, combining the clinical information with neural imaging data. These models can be used to identify the variables that are most predictive of a specific outcome, like whether a medication can improve mood or symptoms. These models can be used to determine the patient's response to an existing treatment and help doctors maximize the effectiveness of the treatment currently being administered.

A new generation employs machine learning techniques such as supervised and classification algorithms such as regularized logistic regression, and tree-based methods to integrate the effects of several variables to improve the accuracy of predictive. These models have been proven to be effective in predicting the outcome of treatment, such as response to antidepressants. These methods are becoming more popular in psychiatry, and are likely to be the norm in future treatment.

Research into depression's underlying mechanisms continues, as well as ML-based predictive models. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This theory suggests that the treatment for depression will be individualized based on targeted treatments that target these neural circuits to restore normal function.

Internet-based-based therapies can be an option to achieve this. They can offer a more tailored and individualized experience for patients. A study showed that an internet-based program improved symptoms and provided a better quality life for MDD patients. Furthermore, a randomized controlled study of a personalised approach to treating depression showed an improvement in symptoms and fewer adverse effects in a significant percentage of participants.

Predictors of side effects

In the treatment of depression the biggest challenge is predicting and determining which antidepressant medications will have very little or no side effects. Many patients take a trial-and-error approach, using various medications prescribed before finding one that is safe and effective. Pharmacogenetics offers a new and exciting way to select antidepressant medications that is more effective and specific.

There are many predictors that can be used to determine the antidepressant that should be prescribed, including gene variations, phenotypes of the patient such as gender or ethnicity and the presence of comorbidities. However finding the most reliable and reliable predictive factors for a specific treatment is likely to require randomized controlled trials with much larger samples than those normally enrolled in clinical trials. This is due to the fact that the identification of moderators or interaction effects can be a lot more difficult in trials that only focus on a single instance of treatment per person instead of multiple sessions of treatment over a period of time.

Furthermore the prediction of a patient's response will likely require information about comorbidities, symptom profiles and the patient's own experience of tolerability and effectiveness. There are currently only a few easily measurable sociodemographic variables as well as clinical variables are consistently associated with response to MDD. These include age, gender and race/ethnicity as well as BMI, SES and the presence of alexithymia.

The application of pharmacogenetics in treatment for depression is in its beginning stages, and many challenges remain. First, it is important to have a clear understanding and definition of the genetic factors that cause depression, and an understanding of an accurate predictor of treatment response. In addition, ethical concerns such as privacy and the appropriate use of personal genetic information must be carefully considered. Pharmacogenetics could eventually reduce stigma associated with mental health treatment and improve the outcomes of treatment. As with all psychiatric approaches it is crucial to give careful consideration and implement the plan. In the moment, it's recommended to provide patients with an array of depression medications that are effective and encourage patients to openly talk with their physicians.